<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231683</url>
  </required_header>
  <id_info>
    <org_study_id>EC 200801014</org_study_id>
    <nct_id>NCT03231683</nct_id>
  </id_info>
  <brief_title>Use of S+Ketamine During Target-Controlled Intravenous Anaesthesia After Abdominal Hysterectomy</brief_title>
  <official_title>The Use of S+Ketamine Versus Placebo During Target-Controlled Intravenous Anaesthesia to Reduce Morphine Consumption and Side Effects After Abdominal Hysterectomy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KK Women's and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KK Women's and Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to investigate the effect of low dose S+ ketamine compared to placebo&#xD;
      on cumulative morphine consumption at 24 hours in 90 women undergoing open abdominal&#xD;
      hysterectomy with remifentanil-propofol target controlled infusion (TCI) in KK Women's and&#xD;
      Children's Hospital. The secondary aims are to investigate the use of low dose S+ ketamine on&#xD;
      the incidence of nausea, vomiting, pruritus (opioid side effect), sedation score and psycho&#xD;
      mimetic assessment compared to placebo group. The investigators propose to conduct a double&#xD;
      blinded, randomized controlled study in women undergoing open abdominal hysterectomy with&#xD;
      remifentanil-propofol TCI. (1) Treatment Group: intravenous ketamine 0.5 mg/kg at the&#xD;
      beginning and 0.5 mg/kg 20 minutes before extubation. (2) Control Group: intravenous normal&#xD;
      saline (as placebo) at the beginning and 20 minutes before extubation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A number of 90 American Society of Anesthesiologists (ASA) I and II patients undergoing&#xD;
      elective open abdominal hysterectomies will be randomly distributed in two groups of 45&#xD;
      patient's each and assigned to receive one of the of the following:&#xD;
&#xD;
        1. Treatment Group: intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and&#xD;
           0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according&#xD;
           to Minto model and propofol infusion according to Marsh model through target control&#xD;
           infusion pump.&#xD;
&#xD;
        2. Control Group: intravenous normal saline (as placebo, with similar volume) at the&#xD;
           beginning and 20 minutes before extubation along with remifentanil according to Minto&#xD;
           model and propofol according to Schnider model through target control infusion pump.&#xD;
&#xD;
      Randomization procedure is performed by the unblinded study team investigator. Patients will&#xD;
      be randomized to either the treatment or control groups with a 1:1 allocation ratio. Sequence&#xD;
      generation will be performed using a computerized random number generator, employing a&#xD;
      permuted block randomization scheme. Allocation concealment will be maintained by having the&#xD;
      random numbers pre-generated by an off-site statistician who will not be involved in subject&#xD;
      recruitment. Implementation will be via serially numbered opaque sealed envelopes.&#xD;
&#xD;
      Throughout the study period, blinded study members will perform drug administration and data&#xD;
      collection, while unblinded study members will be in charge for the investigational drug&#xD;
      storage, dispensing and preparation. Any premature unblinding (e.g. accidental unblinding,&#xD;
      unblinding due a serious adverse event) of the investigational product will be promptly&#xD;
      documented and explained. In the case of adverse effect or severe adverse effect requiring&#xD;
      information on the study treatment to manage a patient, the treatment code of the patient&#xD;
      will be unblinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Cumulative morphine consumption at 24 hours</measure>
    <time_frame>1 day</time_frame>
    <description>Post-operative Cumulative morphine consumption at 24 hours will be measured in the S-ketamine group compared to the placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of nausea</measure>
    <time_frame>1 day</time_frame>
    <description>The use of low dose S-ketamine will reduce the incidence of nausea / vomiting, pruritus (opioid side effect) compared to placebo in women undergoing open abdominal hysterectomy with remifentanil-propofol target controlled infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vomiting</measure>
    <time_frame>1 day</time_frame>
    <description>The use of low dose S-ketamine will reduce the incidence of nausea / vomiting, pruritus (opioid side effect) compared to placebo in women undergoing open abdominal hysterectomy with remifentanil-propofol target controlled infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pruritus</measure>
    <time_frame>1 day</time_frame>
    <description>The use of low dose S-ketamine will reduce the incidence of nausea / vomiting, pruritus (opioid side effect) compared to placebo in women undergoing open abdominal hysterectomy with remifentanil-propofol target controlled infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Ketamine</condition>
  <condition>Anesthesia</condition>
  <condition>Morphine</condition>
  <condition>Hysterectomy</condition>
  <arm_group>
    <arm_group_label>Esketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline and remifentanil to be given alongside with propofol through target control infusion pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model</description>
    <arm_group_label>Esketamine</arm_group_label>
    <other_name>S+ ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Esketamine</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Esketamine</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female ASA I/II patients above age of 21 years old scheduled gynecological open&#xD;
             surgery for benign condition (fibroids, adenomyosis), who are willing and able to give&#xD;
             written informed consent for participation in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the use of S+ ketamine, as listed in the product label e.g.&#xD;
             untreated or insufficiently treated thyroid hyperfunction, unstable angina pectoris or&#xD;
             myocardial infarction within the last 6 months, diseases of the central nervous&#xD;
             system, increased intraocular pressure and perforating ocular injuries, surgical&#xD;
             procedures in the upper respiratory tract;&#xD;
&#xD;
          -  History of drug or alcohol abuse;&#xD;
&#xD;
          -  Regular use of analgesics, or use of opioids within 12 hours of surgery;&#xD;
&#xD;
          -  Chronic use of benzodiazepine or neuroleptics;&#xD;
&#xD;
          -  Thyroid replacement hormone;&#xD;
&#xD;
          -  History of ischaemic heart disease, hypertension, psychiatric disorder;&#xD;
&#xD;
          -  BMI&gt; 30kg/m2;&#xD;
&#xD;
          -  Laparoscopic surgery converted to open surgery;&#xD;
&#xD;
          -  Pregnant or breast feeding females.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farida Ithnin, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>KK Women's and Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kk Women'S and Children'S Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

